The Food and Drug Administration yesterday alerted health care professionals and patients not to use drug products produced by Cantrell Drug Co., including opioid products and other drugs intended for sterile injection, citing serious deficiencies in the company’s compounding operations. “Despite the FDA’s concerns about egregious conditions observed at Cantrell’s facility, during several inspections, with the most recent in 2017, the company continued to compound and distribute drugs without adequately addressing their potentially dangerous conditions,” said FDA Commissioner Scott Gottlieb, M.D. “This reckless activity threatens patient safety and will not be tolerated.” FDA has sought legal action to prevent the company from further producing and distributing drugs. It said health care professionals should immediately check their medical supplies, quarantine any drug products from the company and not administer them to patients. The agency is not aware of illness reports associated with the products, but asks health care professionals to report any associated adverse events or quality problems to its MedWatch program.
Insights and Analysis
East Alabama Medical Center in Opelika treated patients in early March for a tornado that claimed 23 lives and underscored the importance of natural disaster…
The Food and Drug Administration today proposed reclassifying surgical staplers for internal use as moderate-risk rather than low-risk medical devices.
The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the…
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
We must address the racial, ethnic and socioeconomic disparities that increase the risk of negative perinatal outcomes for women of color.
AHA Executive Vice President Maryjane Wurth previews AHA’s Team Training Conference, where different interdisciplinary groups from diverse health care settings…